In contrast, approximately 50% of NSCLC patients who progress after EGFR-TKI failure harbor secondary and concomitant gene mutations, indicating that they have the opportunity to undergo other targeted therapies (e.g., savolitinib for MET mutation) (4). Here, EGFR is linked to non-small cell lung carcinoma.